Exciting day for the lab with the publication of one of our longest-running stories. Now online at @natcomms.nature.com, a preclinical --> clinical translational story of an immunotherapy combination for pancreatic cancer, culminating in a postive Phase 1 trial! www.nature.com/articles/s41...
Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives - Nature Communications
The CXCR4-CXCL12 axis drives immune exclusion and immunosuppression in pancreatic cancer. Here, the authors report a single-arm phase 2 study of metastatic pancreatic cancer evaluating motixafortide (...
www.nature.com
August 21, 2026 at 3:27 PM
Exciting day for the lab with the publication of one of our longest-running stories. Now online at @natcomms.nature.com, a preclinical --> clinical translational story of an immunotherapy combination for pancreatic cancer, culminating in a postive Phase 1 trial! www.nature.com/articles/s41...
Wake up. Take your Dose. Which treats R/R follicular lymphoma?
A. Monomethyl fumarate
B. Morphine
C. Mosunetuzumab
D. Motixafortide
See the thread
#PhunQuiz #MedSky #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmSky #PharmacyStudents #NAPLEX #PTCB #PharmacyTechnicians
A. Monomethyl fumarate
B. Morphine
C. Mosunetuzumab
D. Motixafortide
See the thread
#PhunQuiz #MedSky #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmSky #PharmacyStudents #NAPLEX #PTCB #PharmacyTechnicians
March 8, 2025 at 2:17 PM
Wake up. Take your Dose. Which treats R/R follicular lymphoma?
A. Monomethyl fumarate
B. Morphine
C. Mosunetuzumab
D. Motixafortide
See the thread
#PhunQuiz #MedSky #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmSky #PharmacyStudents #NAPLEX #PTCB #PharmacyTechnicians
A. Monomethyl fumarate
B. Morphine
C. Mosunetuzumab
D. Motixafortide
See the thread
#PhunQuiz #MedSky #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmSky #PharmacyStudents #NAPLEX #PTCB #PharmacyTechnicians
Just In: ( NASDAQ: #BLRX ) BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
#StockMarket #News
#StockMarket #News
October 16, 2024 at 6:40 PM
An early-stage trial found encouraging outcomes with motixafortide, cemiplimab, gemcitabine, and nab-paclitaxel in newly diagnosed pancreatic cancer that had spread. @kenolivelab.bsky.social @columbiacancer.bsky.social #pancsm #oncology
Full story ➡️: www.onclive.com/view/a-new-c...
Full story ➡️: www.onclive.com/view/a-new-c...
A New Combination Therapy Shows Promise in Metastatic Pancreatic Cancer | OncLive
Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
www.onclive.com
September 25, 2026 at 3:30 PM
An early-stage trial found encouraging outcomes with motixafortide, cemiplimab, gemcitabine, and nab-paclitaxel in newly diagnosed pancreatic cancer that had spread. @kenolivelab.bsky.social @columbiacancer.bsky.social #pancsm #oncology
Full story ➡️: www.onclive.com/view/a-new-c...
Full story ➡️: www.onclive.com/view/a-new-c...
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Making sure you're not a bot!
scientiasalut.gencat.cat
August 21, 2026 at 11:07 AM
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Product Description
Motixafortide (CAS: 1447754‑15‑9) is a chemically synthesized, high-purity CXCR4 receptor antagonist designed for molecular and cellular research applications. #GMP
arizona-mall.com/product/moti...
Motixafortide (CAS: 1447754‑15‑9) is a chemically synthesized, high-purity CXCR4 receptor antagonist designed for molecular and cellular research applications. #GMP
arizona-mall.com/product/moti...
Motixafortide (CAS: 1447754-15-9) – Purity 99.88% | GMP Factory
Motixafortide is a high-affinity CXCR4 antagonist designed for molecular mechanism research, in vitro signal transduction analysis, and cell migration studies. It selectively inhibits the C-X-C chemokine receptor type 4 (CXCR4), making it an essential tool for probing chemokine receptor-mediated cellular localization and signaling pathways (IC₅₀ ~0.4–4.5 nM).
arizona-mall.com
December 26, 2025 at 5:09 PM
Product Description
Motixafortide (CAS: 1447754‑15‑9) is a chemically synthesized, high-purity CXCR4 receptor antagonist designed for molecular and cellular research applications. #GMP
arizona-mall.com/product/moti...
Motixafortide (CAS: 1447754‑15‑9) is a chemically synthesized, high-purity CXCR4 receptor antagonist designed for molecular and cellular research applications. #GMP
arizona-mall.com/product/moti...
Motixafortide (CAS: 1447754-15-9) – Purity 99.88% | GMP Factory
Motixafortide is a potent and selective CXCR4 antagonist used in tumor microenvironment, stem cell mobilization, and immuno-oncology research. GMP-quality peptide with ≥99.88% purity. For laboratory use only.（For wholesale prices,…
Motixafortide is a potent and selective CXCR4 antagonist used in tumor microenvironment, stem cell mobilization, and immuno-oncology research. GMP-quality peptide with ≥99.88% purity. For laboratory use only.（For wholesale prices,…
Motixafortide (CAS: 1447754-15-9) – Purity 99.88% | GMP Factory
Motixafortide is a potent and selective CXCR4 antagonist used in tumor microenvironment, stem cell mobilization, and immuno-oncology research. GMP-quality peptide with ≥99.88% purity. For laboratory use only.（For wholesale prices, other specifications and uses, please consult our staff）
arizona-mall.com
August 6, 2025 at 2:03 PM
Motixafortide (CAS: 1447754-15-9) – Purity 99.88% | GMP Factory
Motixafortide is a potent and selective CXCR4 antagonist used in tumor microenvironment, stem cell mobilization, and immuno-oncology research. GMP-quality peptide with ≥99.88% purity. For laboratory use only.（For wholesale prices,…
Motixafortide is a potent and selective CXCR4 antagonist used in tumor microenvironment, stem cell mobilization, and immuno-oncology research. GMP-quality peptide with ≥99.88% purity. For laboratory use only.（For wholesale prices,…
Development and Validation of the LC–MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
Development and Validation of the LC–MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma
Introduction Motixafortide, a CXCR4 antagonist, and filgrastim, a granulocyte colony-stimulating factor, have shown significant potential in enhancing hematopoietic stem cell mobilization and improv...
analyticalsciencejournals.onlinelibrary.wiley.com
May 27, 2025 at 7:19 PM
Development and Validation of the LC–MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
[New Blog Post] Bulk NGS masks the truth in AML. Retrospective BLAST trial data shows that single-cell DNA+Protein reveals the CXCR4 biomarkers that actually predict patient response. Stop averaging. 🧬 www.missionbio.com/company/blog...
Clinical Utility of Single-Cell CXCR4 Biomarker Stratification for Motixafortide Treated Acute Myeloid Leukemia Patients | Mission Bio
Discover how single-cell CXCR4 biomarker stratification revealed hidden clinical utility for Motixafortide in AML patients, overcoming the limitations of bulk sequencing.
www.missionbio.com
March 20, 2026 at 5:34 PM
[New Blog Post] Bulk NGS masks the truth in AML. Retrospective BLAST trial data shows that single-cell DNA+Protein reveals the CXCR4 biomarkers that actually predict patient response. Stop averaging. 🧬 www.missionbio.com/company/blog...
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study academic.oup.com/oncolo/advan... #hvhebron #ad [Text complet] @OncJournal
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study
AbstractBackground. The MORPHEUS platform comprised multiple open-label, randomized, phase Ib/II trials to identify early signals with different treatment
academic.oup.com
March 4, 2026 at 3:42 PM
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study academic.oup.com/oncolo/advan... #hvhebron #ad [Text complet] @OncJournal
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of ... - Yahoo Finance - goo.gl/alerts/ZKanmb #GoogleAlerts
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from t...
goo.gl
May 30, 2025 at 10:31 PM
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of ... - Yahoo Finance - goo.gl/alerts/ZKanmb #GoogleAlerts
BioLineRx presented @ ASCO
*CheMo4METPANC Ph2 motixafortide data
$BLRX
finance.yahoo.com/news/bioline...
*CheMo4METPANC Ph2 motixafortide data
$BLRX
finance.yahoo.com/news/bioline...
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from t...
finance.yahoo.com
June 2, 2025 at 6:36 PM
BioLineRx presented @ ASCO
*CheMo4METPANC Ph2 motixafortide data
$BLRX
finance.yahoo.com/news/bioline...
*CheMo4METPANC Ph2 motixafortide data
$BLRX
finance.yahoo.com/news/bioline...
BioLineRx Receives Notice of Allowance for US Patent on Motixafortide Manufacturing Process - Best Stocks: BioLineRx… https://news.google.com/rss/articles/CBMiRWh0dHBzOi8vYmVzdHN0b2Nrcy5jb20vYmlvbGluZXJ4LXJlY2VpdmVzLW5vdGljZS1vZi1hbGxvd2FuY2UtZm9yLXVzL9IBAA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
March 4, 2024 at 4:26 PM
BioLineRx Receives Notice of Allowance for US Patent on Motixafortide Manufacturing Process - Best Stocks: BioLineRx… https://news.google.com/rss/articles/CBMiRWh0dHBzOi8vYmVzdHN0b2Nrcy5jb20vYmlvbGluZXJ4LXJlY2VpdmVzLW5vdGljZS1vZi1hbGxvd2FuY2UtZm9yLXVzL9IBAA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
BioLineRx secures new patent for motixafortide… https://news.google.com/rss/articles/CBMidmh0dHBzOi8vYXUuaW52ZXN0aW5nLmNvbS9uZXdzL3N0b2NrLW1hcmtldC1uZXdzL2Jpb2xpbmVyeC1zZWN1cmVzLW5ldy1wYXRlbnQtZm9yLW1vdGl4YWZvcnRpZGUtcHJvZHVjdGlvbi05M0NILTMxMzk5MjjSAQA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
March 4, 2024 at 1:14 PM
BioLineRx secures new patent for motixafortide… https://news.google.com/rss/articles/CBMidmh0dHBzOi8vY2EuaW52ZXN0aW5nLmNvbS9uZXdzL3N0b2NrLW1hcmtldC1uZXdzL2Jpb2xpbmVyeC1zZWN1cmVzLW5ldy1wYXRlbnQtZm9yLW1vdGl4YWZvcnRpZGUtcHJvZHVjdGlvbi05M0NILTMyODczMzDSAQA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
March 4, 2024 at 12:54 PM
BioLineRx secures new patent for motixafortide… https://news.google.com/rss/articles/CBMidmh0dHBzOi8vdWsuaW52ZXN0aW5nLmNvbS9uZXdzL3N0b2NrLW1hcmtldC1uZXdzL2Jpb2xpbmVyeC1zZWN1cmVzLW5ldy1wYXRlbnQtZm9yLW1vdGl4YWZvcnRpZGUtcHJvZHVjdGlvbi05M0NILTMzNjM3OTHSAQA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
March 4, 2024 at 12:49 PM
BioLineRx secures new patent for motixafortide… https://news.google.com/rss/articles/CBMid2h0dHBzOi8vd3d3LmludmVzdGluZy5jb20vbmV3cy9zdG9jay1tYXJrZXQtbmV3cy9iaW9saW5lcngtc2VjdXJlcy1uZXctcGF0ZW50LWZvci1tb3RpeGFmb3J0aWRlLXByb2R1Y3Rpb24tOTNDSC0zMzIzMTYz0gEA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
March 4, 2024 at 12:44 PM
JUST IN: ( NASDAQ: #BLRX ) BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd.
#StockMarket #News
#StockMarket #News
November 21, 2024 at 11:35 AM
BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping#Israel#Tel_Aviv#BioLineRx#motixafortide#GLIX1
BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping
BioLineRx Ltd. announces its Q3 2025 financial results, alongside an update on corporate initiatives, including joint venture developments.
third-news.com
November 24, 2025 at 12:23 PM
BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping#Israel#Tel_Aviv#BioLineRx#motixafortide#GLIX1
BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting#Israel#Tel_Aviv#BioLineRx#pancreatic_cancer#motixafortide
BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting
BioLineRx Ltd. reveals promising data from its combination therapy trial for pancreatic cancer, showcasing a significant advance in treatment options for this challenging disease.
third-news.com
May 30, 2025 at 11:13 AM
BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting#Israel#Tel_Aviv#BioLineRx#pancreatic_cancer#motixafortide
BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments#Israel#Tel_Aviv#BioLineRx#APHEXDA#motixafortide
BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments
BioLineRx has reported its Q1 2025 financial results, showcasing significant advancements in drug development and corporate strategies in oncology and rare diseases.
third-news.com
May 27, 2025 at 11:16 AM
BioLineRx Delivers Promising Progress in Q1 2025 Financial Results and Corporate Developments#Israel#Tel_Aviv#BioLineRx#APHEXDA#motixafortide
#BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
https://www.stocktitan.net/news/BLRX/bio-line-rx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-zu9edtosljhn.html
https://www.stocktitan.net/news/BLRX/bio-line-rx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-zu9edtosljhn.html
November 21, 2024 at 11:30 AM
#BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
https://www.stocktitan.net/news/BLRX/bio-line-rx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-zu9edtosljhn.html
https://www.stocktitan.net/news/BLRX/bio-line-rx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-zu9edtosljhn.html
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
www.viv-media.com/infozx-34741...
www.viv-media.com/infozx-34741...
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
www.viv-media.com
October 16, 2024 at 3:50 PM
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
www.viv-media.com/infozx-34741...
www.viv-media.com/infozx-34741...